Armata Pharmaceuticals (ARMP) Accumulated Expenses (2014 - 2026)

Armata Pharmaceuticals (ARMP) has 13 years of Accumulated Expenses data on file, last reported at $2.8 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 108.98% year-over-year to $2.8 million; the trailing twelve-month figure through Mar 2026 stood at $2.8 million (up 108.98% YoY), and the FY2025 full-year result was $2.2 million, down 3.9% from the prior year.
• Accumulated Expenses rose to $2.8 million in Q1 2026, from $2.2 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $2.8 million in Q1 2026 to a low of $768000.0 in Q4 2023.
• A 5-year average of $1.6 million and a median of $1.6 million in 2025 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses slumped 57.99% in 2023 and soared 196.88% in 2024, its largest moves.
• Tracing ARMP's Accumulated Expenses over 5 years: stood at $1.8 million in 2022, then tumbled by 57.99% to $768000.0 in 2023, then soared by 196.88% to $2.3 million in 2024, then decreased by 3.9% to $2.2 million in 2025, then climbed by 28.48% to $2.8 million in 2026.
• Business Quant data shows ARMP's Accumulated Expenses at $2.8 million in Q1 2026, $2.2 million in Q4 2025, and $1.8 million in Q3 2025.